AKAlkesh Kumar Khurana

Alkesh Kumar Khurana

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alkesh Kumar Khurana has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Decoding moxifloxacin resistance in pre-XDR tuberculosis using MGIT 960 and MYCOTB AST

    by D Daniel Raj, Anand Kumar Maurya, Shashank Purwar, Sagar Khadanga, Jitendra Singh, Alkesh Kumar Khurana, Sowmya Dhawan, Debasis Biswas

  • Open Access

    Rapid Detection of Resistance Mutations in Multidrug‐Resistant Tuberculosis With GenoType MTBDR sl Assay

    by Shaina Gaikwad, Antisha Tiwari, Jitendra Singh, Alkesh Kumar Khurana, Sagar Khadanga, Shashank Purwar, Debasis Biswas, Anand Kumar Maurya

    Background: Multidrug‐resistant tuberculosis (MDR‐TB) is becoming a major threat to the global control of tuberculosis (TB). The situation worsens when fluoroquinolone (FQ) and second‐line injectable (SLID) resistant strains are involved. This study assesses the utility of MTBDR sl V2.0 line probe assay (LPA) in identifying resistance patterns to FQ and SLID in MDR‐TB isolates. Methods: A total of 74 MDR‐TB isolates were tested for genetic mutations that confer resistance to FQs and against SLIDs by applying the GenoType MTBDR sl V2.0 LPA. This assay targets resistance‐associated mutations in the gyrA and gyrB genes for FQ resistance, and in the rrs and eis genes for resistance to aminoglycosides and capreomycin. Results: Of the 74 isolates examined, 14 (18.9%) had FQ resistance. Most of these isolates had mutations in the gyrA gene, most commonly at codon A90V (6.7%), followed by D94G (5.4%), and various D94 variations. No mutations were found in the rrs, gyrB, or eis genes, and no resistance to SLIDs was found. With no discernible contribution from rrs, gyrB , or eis genes, our results emphasize gyrA mutations, particularly A90V and D94G, as important molecular markers of FQ resistance. Conclusion: The MTBDR sl V2.0 assay demonstrated operational utility for rapid detection of resistance‐associated mutations related to FQs and SLID drugs in MDR‐TB isolates. Its rapid turnaround time expanded mutation coverage, and applicability in routine diagnostic settings make it a useful tool for molecular resistance profiling in high TB‐burden settings.

  • Open Access

    Coexistence of Pulmonary Thromboembolism, Pulmonary Tuberculosis and Granulomatosis with Polyangiitis

    by Sai T Pavirala, Alkesh Khurana, Kirti Kadian, Abhishek Goyal

    Granulomatosis with polyangiitis (GPA) is a rare autoimmune disease with multi‐system involvement. It involves the upper respiratory tract, lungs and kidneys. A 36-year-old female patient presented with complaints of low-grade fever, dry cough and loss of appetite initially followed by dyspnea, purpuric skin lesions, right lower limb swelling with pain and redness. Her chest radiograph revealed right upper lobe cavitary lesion with consolidation in right lower lobe. Mycobacterium tuberculosis was detected in sputum and Broncho alveolar lavage (BAL) via Cartridge based nucleic acid amplification assay (CB-NAAT). Later, Computed Tomography Pulmonary Angiography (CTPA) revealed bilateral pulmonary artery thromboembolism. Furthermore, her C-ANCA was positive, serum creatinine was rising, urine microscopy had red cell casts and lower limb venous doppler revealed DVT. Histopathological examination of the skin lesion revealed vasculitis. Based on the above findings, diagnosis of GPA was comfortably made. Patient improved with pulse steroids, cyclophosphamide, anticoagulants and anti-tuberculous therapy (ATT).


  • Cytohistological findings and diagnostic challenges in rare pediatric pulmonary mesenchymal malignancies: A report of two cases

    by Karunagaran Balaji, Swalaha Sadaf Siddique, Ujjawal Khurana, Garima Goel, Ashwani Tandon, Deepti Joshi, Narendra Chaudhary, Alkesh Kumar Khurana, Abhishek Goyal

    Pulmonary mesenchymal tumors are uncommon neoplasms and the data available on their clinical, cytohistomorphological, immunohistochemical, and molecular findings are limited, leading to difficulty in timely diagnosis and management. Case 1: A 12‐year‐old boy presented with a right endobronchial mass. Imprint smears from endobronchial biopsy revealed moderately pleomorphic spindle cell tumor arranged in fascicles and perivascular pattern with attached myxoid material showing occasional mitotic activity suggesting a cytological diagnosis of sarcoma. Biopsy also displayed similar morphology. Extensive immunohistochemistry (IHC) showed diffuse SMA, focal AE1/AE3, and diffuse ALK positivity along with a MIB/Ki67 index of 30%–40% leading to the diagnosis of inflammatory myofibroblastic tumor (IMT; Sarcoma grade). Case 2: A 8‐year‐old boy presented with a huge left‐sided mass replacing the entire lung parenchyma and eroding adjoining ribs. Pleural fluid cytology revealed vague clusters of PAS‐positive diastase‐sensitive small atypical cells with associated inflammatory cells in the hemorrhagic background, suggesting a diagnosis of malignant small round blue cell tumor. Trucut biopsy from the mass showed spindled to round cells showing diffuse positivity with CD99 and BCL‐2. Molecular studies with reverse transcription‐PCR (RT‐PCR) for SYT‐SSX and EWS‐FLI1 were negative for synovial sarcoma and Ewing's sarcoma, respectively. Given the clinical setting, PAS positivity, IHC, and molecular studies, the diagnosis of tumors of uncertain differentiation with the possibility of Ewing's sarcoma family of tumors (ESFT) with a translocation between EWS1 and other ETS—family members (ERG, FEV, ETV1, E1AF, etc.) was suggested.


  • Effect of pulmonary rehabilitation in patients with post-tuberculosis sequelae with functional limitation

    by Aqeel Hussain, Alkesh Kumar Khurana, Abhishek Goyal, S.Y. Kothari, Raj Krishnan Soman, Sai Tej, Abhijit Pakhare


  • Open Access

    Diagnostic Performance of Multiplex PCR for Detection of Mycobacterium tuberculosis Complex in Presumptive Pulmonary Tuberculosis Patients and Its Utility in Smear Negative Specimens

    by Lonika Lodha, Shivkumar Rashmi Mudliar, Jitendra Singh, Anand Maurya, Alkesh Kumar Khurana, Sagar Khadanga, Sarman Singh

    Objective The primary objective of this study was to assess the diagnostic performance of multiplex polymerase chain reaction (mPCR) for the detection of Mycobacterium tuberculosis complex (MTBC) in presumptive pulmonary TB patients, in the setting of a tertiary level teaching hospital in central India, in comparison to liquid culture using BACTEC mycobacteria growth indicator tubes (MGIT) 960 TB system as the gold standard. The secondary objective was to assess the performance of mPCR for Ziehl Neelsen smear negative samples and ascertain the utility of this assay in smear negative samples.Materials and Methods Sputum or bronchoalveolar lavage samples were collected from patients who were adults, aged 18 years or older, presenting with presumptive pulmonary TB, and subjected to three microbiological investigations, that is, Ziehl Neelsen staining, mycobacterial culture using mycobacterial growth indicator tubes in the BD BACTEC MGIT 960 instrument, and the mPCR.Statistical Analysis For statistical analysis, 2 × 2 contingency tables were prepared and analyzed separately for all samples and for smear-negative samples using GraphPad and MedCalc tools. Sensitivity, specificity, positive predictive value, and negative predictive value (NPV) of mPCR were calculated by taking MGIT culture as the reference standard.Results For all samples (n = 114), sensitivity of mPCR for the detection of (MTBC) was 93.48% (95% confidence interval [CI]: 82.10–98.63%), specificity was 95.59% (95% CI: 87.64–99.08%), positive predictive value (PPV) was 93.48% (95% CI: 82.54–97.75%), and NPV was 95.59% (95% CI: 87.87–98.48%). For smear negative samples (n = 80), sensitivity was 80.00% (95% CI: 51.91–95.67%), specificity was 98.46% (95% CI: 91.72–99.96%), PPV was 92.31% (95% CI: 62.80–98.84%), and NPV was 95.52% (95% CI: 88.57–98.33%).Conclusion In this study, we were able to demonstrate the good performance characteristics of the mPCR for the detection of MTBC from clinical samples of patients with presumptive pulmonary tuberculosis, with MGIT liquid culture as the reference standard. It may be concluded that mPCR can be considered equivalent to MGIT culture in terms of clinical decision making and yield of positivity, owing to the good sensitivity and specificity for the detection of MTBC.


  • Open Access

    Role of Thromboelastography and Thromboelastometry in Predicting Risk of Hypercoagulability and Thrombosis in Critically Ill COVID-19 Patients: A Qualitative Systematic Review

    by Sunaina Tejpal Karna, Pooja Singh, Zainab Ahmad Haq, Gaurav Jain, Alkesh Khurana, Saurabh Saigal, Jai Prakash Sharma, Vaishali Waindeskar

    COVID-19,Thromboelastography,Rotational Thromboelastometry,Coagulation assays,Hypercoagulability,Thrombosis


  • Open Access

    Aspergilloma in Non-tuberculous Cavities in the Lung: Not to Get Startled

    by Sai Tej Pavirala, S Anusha Rao, Gaurav Sahu, Alkesh Khurana, Abhishek Goyal

    Aspergillus which is normally found as a colonizer in healthy individuals can manifest in various forms in patients with diseased lung or immunocompromised status. Aspergilloma is one such manifestation whereby the fungus makes its way into preexisting cavities in the lung, the most common underlying etiology being old tuberculous cavities, especially in countries with high TB prevalence. However, we hereby report two cases of Aspergillus infestation as aspergilloma in cavities because of extremely rare causes, namely pulmonary thromboembolism and idiopathic pulmonary fibrosis, respectively.


  • Open Access

    Rituximab-Induced Interstitial Lung Disease: A Stitch in Time Saved Nine

    by Sai Tej, Asha Undrajavarapu, Kirti Kadian, Alkesh Khurana, Abhishek Goyal

    A 59-year-old male was initially diagnosed with pemphigus Vulgaris and received rituximab after a suboptimal clinical response with low-dose steroids and cyclophosphamide. Shortly after the third dose, he had acute interstitial pneumonia which was attributed to rituximab as there were no signs of any infective etiology after a detailed workup. He was put on mechanical ventilation but the dramatic response to pulse steroids helped the patient in early extubation and a favorable outcome.